sgb 1534 has been researched along with ketanserin in 3 studies
| Studies (sgb 1534) | Trials (sgb 1534) | Recent Studies (post-2010) (sgb 1534) | Studies (ketanserin) | Trials (ketanserin) | Recent Studies (post-2010) (ketanserin) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 3,094 | 335 | 283 |
| Protein | Taxonomy | sgb 1534 (IC50) | ketanserin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0021 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.265 | |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | 6.5 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0184 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0027 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.29 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 1.8 | |
| Synaptic vesicular amine transporter | Homo sapiens (human) | 0.18 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagatomo, T; Tsuchihashi, H | 1 |
| Aono, J; Ishizuka, N; Nabata, H; Sakai, K | 1 |
| Aono, J; Hokibara, R; Nagatomo, T; Nakamura, T; Tanaka, Y; Tsuchihashi, H | 1 |
3 other study(ies) available for sgb 1534 and ketanserin
| Article | Year |
|---|---|
Alpha-blocking potencies of antihypertensive agents (prazosin, terazosin, bunazosin, SGB-1534 and ketanserin) having with quinazoline or quinazolinedione as assessed by radioligand binding assay methods in rat brain.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Brain; Cell Membrane; Clonidine; Dihydroalprenolol; Ketanserin; Male; Prazosin; Quinazolines; Radioligand Assay; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1989 |
Mechanism of the hypotensive effect of a novel phenylpiperazine derivative, SGB-1534: antagonism at alpha 1-adrenergic and 5-HT2 receptors.
Topics: Adrenergic alpha-Antagonists; Anesthesia; Animals; Antihypertensive Agents; Decerebrate State; Gastric Fundus; Guinea Pigs; In Vitro Techniques; Ketanserin; Male; Muscle Contraction; Muscle, Smooth; Muscle, Smooth, Vascular; Piperidines; Prazosin; Quinazolines; Rats; Rats, Inbred Strains; Serotonin Antagonists | 1985 |
Effects of ketanserin and 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4(1H,3H)- quinazolinedione monohydrochloride (SGB-1534), anti-hypertensive agents, on 3H-serotonin and 3H-ketanserin bindings to serotonergic (5HT1 and 5HT2) receptors in dog brain
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Brain Chemistry; Dogs; Female; In Vitro Techniques; Ketanserin; Male; Muscle, Smooth, Vascular; Quinazolines; Receptors, Serotonin; Serotonin | 1988 |